API manufacturer (ex-Glenmark Life Sciences) making generic and complex active pharmaceutical ingredients plus CDMO services.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 2 | 2 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 400 | 751 | 2.0k | 2.1k | 2.3k | 2.8k | 3.0k | 3.3k |
| Borrowings | 0 | 0 | 3 | 19 | 17 | 57 | 60 | 57 |
| Other Liabilities | 1.3k | 1.2k | 414 | 545 | 501 | 537 | 563 | 594 |
| Total Liabilities | 1.7k | 2.0k | 2.5k | 2.7k | 2.9k | 3.4k | 3.6k | 4.0k |
| AssetsFixed Assets | 546 | 573 | 595 | 781 | 805 | 955 | 969 | 1.0k |
| CWIP | 11 | 14 | 92 | 62 | 106 | 102 | 173 | 273 |
| Investments | 0 | 0 | 0 | 0 | 0 | 478 | 634 | 780 |
| Other Assets | 1.2k | 1.4k | 1.8k | 1.9k | 1.9k | 1.9k | 1.9k | 1.9k |
| Total Assets | 1.7k | 2.0k | 2.5k | 2.7k | 2.9k | 3.4k | 3.6k | 4.0k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Cash from Investing | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Cash from Financing | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (21.1×) and current (23.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 6.6% growth and a 21× exit, ₹1070 only delivers your return if you pay ₹563. The price is currently baking in 20% growth.
EPS grows 6.6%/yr for 5 years, then fades to 6% over 2, exits at 21×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 6.6% | 49.05 |
| FY28 | 6.6% | 52.28 |
| FY29 | 6.6% | 55.73 |
| FY30 | 6.6% | 59.41 |
| FY31 | 6.6% | 63.33 |
| FY32 | 6.3% ·fade | 67.32 |
| FY33 | 6.0% ·fade | 71.36 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.